Abstract Objective To investigate the effects of erythropoietin (EPO) on the neuronal proliferation and apoptosis in neonatal rats after infection-induced brain injury and the neuroprotective mechanism of EPO in neonatal rats with infection-induced brain injury. Methods Twenty-six two-day-old neonatal rats were randomly divided into 3 groups: control group (intraperitoneally given an equal volume of normal saline), lipopolysaccharide (LPS) group (intraperitoneally given LPS 0.6 mg/kg), and EPO group (intraperitoneally given LPS 0.6 mg/kg and EPO 5 000 U/kg). These groups were injected with respective drugs for 5 consecutive days. Meanwhile, each group was intraperitoneally injected with 5-bromo-2'-deoxyuridine (BrdU) (50 mg/kg) once a day for 5 consecutive days. The expression of BrdU and cleaved Caspase-3 in the hippocampal dentate gyrus was detected by immunohistochemistry at 24 hours after the last injection. Results The number of neuronal cells in the hippocampal dentate gyrus in the LPS and EPO groups was significantly greater than in the control group (PPPPPConclusions EPO can promote hippocampal neuronal proliferation and reduce neuronal apoptosis in neonatal rats after infection-induced brain injury.
XU Fa-Lin,GUO Jia-Jia,ZHUANG Fang-Li et al. Effects of erythropoietin on neuronal proliferation and apoptosis in neonatal rats after infection-induced brain injury[J]. CJCP, 2014, 16(3): 290-294.
XU Fa-Lin,GUO Jia-Jia,ZHUANG Fang-Li et al. Effects of erythropoietin on neuronal proliferation and apoptosis in neonatal rats after infection-induced brain injury[J]. CJCP, 2014, 16(3): 290-294.
Johnston MV, Fatemi A, Wilson MA, et al. Treatment advances in neonatal neuroprotection and neurointensive care[J]. Lancet Neurol, 2011, 10(4): 372-382.
[2]
Han W, Song J, Liu A, et al. Trends in live births in the past 20 years in Zhengzhou, China[J]. Acta Obstet Gynecol Scand, 2011, 90(4): 332-337.
[3]
Rutherford M, Ramenghi LA, Edwards AD, et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial[J]. Lancet Neurol, 2010, 9(1): 39-45.
Mallard C, Wang X. Infection-induced vulnerability of perinatal brain injury[J]. Neurol Res Int, 2012, 2012: 102153.
[8]
Graf AE, Haines KM, Pierson CR, et al. Perinatal inflammation results in decreased oligodendrocyte numbers in adulthood[J]. Life Sci, 2014, 94(2): 164-171.
[9]
Du X, Fleiss B, Li H, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development[J]. PloS One, 2011, 6(5): e19583.
[10]
Neubauer AP, Voss W, Wachtendorf M, et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants[J]. Ann Neurol, 2010, 67(5): 657-666.
[11]
Fan X, Heijnen CJ, van der KOOIJ MA, et al. Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice[J]. Pediatr Res, 2011, 69(1): 56-61.
[12]
Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy[J]. Pediatrics, 2009, 124(2): e218-226.
[13]
Chen H, Spagnoli F, Burris M, et al. Nanoerythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia and ischemia[J]. Stroke, 2012, 43(3): 884-887.
[14]
Kumral A, Uysal N, Tugyan K, et al. Erythropoietin improves longterm spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats[J]. Behav Brain Res, 2004, 153(1): 77-86.
[15]
Shen Y, Yu HM, Yuan TM, et al. Erythropoietin attenuates white matter damage, proinflammatory cytokine and chemokine induction in developing rat brain after intra-uterine infection[J]. Neuropathology, 2009, 29(5): 528-535.
[16]
Mizuno K, Hida H, Masuda T, et al. Pretreatment with low doses of erythropoietin ameliorates brain damage in periventricular leukomalacia by targeting late oligodendrocyte progenitors: a rat model[J]. Neonatology, 2008, 94(4): 255-266.
[17]
Taupin P. BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation[J]. Brain Res Rev, 2007, 53(1): 198-214.
